Slovenia
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.84 (0.73 - 0.95) | 2019 | Modelled | IHME |
| 0.89 (0.79 - 1) | 2018 | Modelled | IHME |
| 0.91 (0.79 - 1.03) | 2017 | Modelled | IHME |
| 0.9 (0.79 - 1.02) | 2016 | Modelled | IHME |
| 0.9 (0.77 - 1.02) | 2015 | Modelled | IHME |
| 0.9 (0.78 - 1.02) | 2014 | Modelled | IHME |
| 0.92 (0.80 - 1.04) | 2013 | Modelled | IHME |
| 0.93 (0.82 - 1.06) | 2012 | Modelled | IHME |
| 0.95 (0.84 - 1.08) | 2011 | Modelled | IHME |
| 0.97 (0.84 - 1.11) | 2010 | Modelled | IHME |
| 0.98 (0.85 - 1.12) | 2009 | Modelled | IHME |
| 0.99 (0.87 - 1.12) | 2008 | Modelled | IHME |
| 1 (0.87 - 1.13) | 2007 | Modelled | IHME |
| 1.01 (0.87 - 1.15) | 2006 | Modelled | IHME |
| 1.03 (0.87 - 1.17) | 2005 | Modelled | IHME |
| 1.04 (0.89 - 1.18) | 2004 | Modelled | IHME |
| 1.05 (0.91 - 1.19) | 2003 | Modelled | IHME |
| 1.07 (0.92 - 1.21) | 2002 | Modelled | IHME |
| 1.08 (0.93 - 1.23) | 2001 | Modelled | IHME |
| 1.09 (0.93 - 1.25) | 2000 | Modelled | IHME |
| 1.1 (0.94 - 1.26) | 1999 | Modelled | IHME |
| 1.12 (0.95 - 1.28) | 1998 | Modelled | IHME |
| 1.13 (0.96 - 1.29) | 1997 | Modelled | IHME |
| 1.14 (0.96 - 1.30) | 1996 | Modelled | IHME |
| 1.14 (0.96 - 1.31) | 1995 | Modelled | IHME |
| 1.14 (0.97 - 1.31) | 1994 | Modelled | IHME |
| 1.14 (0.97 - 1.30) | 1993 | Modelled | IHME |
| 1.14 (0.97 - 1.30) | 1992 | Modelled | IHME |
| 1.13 (0.96 - 1.29) | 1991 | Modelled | IHME |
| 1.13 (0.95 - 1.29) | 1990 | Modelled | IHME |
| 1.07 (0.15 - 8.32) | 2015 | Modelled | WHO |
| 1 (0.40 - 1.10) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.06 (0.04 - 0.08) | 2019 | Modelled | IHME |
| 0.07 (0.05 - 0.09) | 2018 | Modelled | IHME |
| 0.07 (0.05 - 0.09) | 2017 | Modelled | IHME |
| 0.07 (0.05 - 0.09) | 2016 | Modelled | IHME |
| 0.07 (0.05 - 0.09) | 2015 | Modelled | IHME |
| 0.06 (0.05 - 0.08) | 2014 | Modelled | IHME |
| 0.06 (0.04 - 0.08) | 2013 | Modelled | IHME |
| 0.05 (0.04 - 0.06) | 2012 | Modelled | IHME |
| 0.04 (0.03 - 0.06) | 2011 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2010 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2009 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2008 | Modelled | IHME |
| 0.04 (0.02 - 0.05) | 2007 | Modelled | IHME |
| 0.04 (0.02 - 0.05) | 2006 | Modelled | IHME |
| 0.03 (0.02 - 0.05) | 2005 | Modelled | IHME |
| 0.04 (0.02 - 0.05) | 2004 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2003 | Modelled | IHME |
| 0.04 (0.03 - 0.05) | 2002 | Modelled | IHME |
| 0.04 (0.03 - 0.06) | 2001 | Modelled | IHME |
| 0.05 (0.04 - 0.07) | 2000 | Modelled | IHME |
| 0.1 (0.07 - 0.14) | 1999 | Modelled | IHME |
| 0.22 (0.15 - 0.30) | 1998 | Modelled | IHME |
| 0.36 (0.25 - 0.48) | 1997 | Modelled | IHME |
| 0.47 (0.33 - 0.64) | 1996 | Modelled | IHME |
| 0.52 (0.36 - 0.71) | 1995 | Modelled | IHME |
| 0.52 (0.37 - 0.71) | 1994 | Modelled | IHME |
| 0.52 (0.36 - 0.70) | 1993 | Modelled | IHME |
| 0.52 (0.36 - 0.69) | 1992 | Modelled | IHME |
| 0.51 (0.35 - 0.67) | 1991 | Modelled | IHME |
| 0.5 (0.34 - 0.65) | 1990 | Modelled | IHME |
| 1.04 (0.14 - 8.39) | 2015 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 22,244 (18,756 - 25,501) | 1990 | Modelled | IHME |
| 22,400 (19,021 - 25,542) | 1991 | Modelled | IHME |
| 22,506 (19,159 - 25,679) | 1992 | Modelled | IHME |
| 22,574 (19,183 - 25,766) | 1993 | Modelled | IHME |
| 22,614 (19,243 - 25,920) | 1994 | Modelled | IHME |
| 22,638 (19,128 - 26,039) | 1995 | Modelled | IHME |
| 22,589 (19,112 - 25,898) | 1996 | Modelled | IHME |
| 22,429 (19,054 - 25,700) | 1997 | Modelled | IHME |
| 22,202 (18,905 - 25,434) | 1998 | Modelled | IHME |
| 21,953 (18,734 - 25,099) | 1999 | Modelled | IHME |
| 21,728 (18,587 - 24,905) | 2000 | Modelled | IHME |
| 21,513 (18,557 - 24,458) | 2001 | Modelled | IHME |
| 21,278 (18,454 - 24,059) | 2002 | Modelled | IHME |
| 21,037 (18,198 - 23,843) | 2003 | Modelled | IHME |
| 20,804 (17,831 - 23,613) | 2004 | Modelled | IHME |
| 20,596 (17,521 - 23,455) | 2005 | Modelled | IHME |
| 20,414 (17,598 - 23,133) | 2006 | Modelled | IHME |
| 20,244 (17,604 - 22,843) | 2007 | Modelled | IHME |
| 20,081 (17,523 - 22,651) | 2008 | Modelled | IHME |
| 19,916 (17,348 - 22,670) | 2009 | Modelled | IHME |
| 19,738 (17,173 - 22,622) | 2010 | Modelled | IHME |
| 19,488 (17,106 - 22,187) | 2011 | Modelled | IHME |
| 19,164 (16,812 - 21,811) | 2012 | Modelled | IHME |
| 18,842 (16,430 - 21,398) | 2013 | Modelled | IHME |
| 18,608 (16,030 - 21,146) | 2014 | Modelled | IHME |
| 18,535 (15,825 - 21,160) | 2015 | Modelled | IHME |
| 18,703 (16,304 - 21,075) | 2016 | Modelled | IHME |
| 18,863 (16,471 - 21,331) | 2017 | Modelled | IHME |
| 18,456 (16,299 - 20,667) | 2018 | Modelled | IHME |
| 17,487 (15,224 - 19,712) | 2019 | Modelled | IHME |
| 21,000 (9,000 - 23,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 7.08 (4.94 - 10.10) | 2019 | Modelled | IHME |
| 7.01 (4.98 - 9.82) | 2018 | Modelled | IHME |
| 6.92 (5.15 - 9.13) | 2017 | Modelled | IHME |
| 6.82 (5.16 - 8.81) | 2016 | Modelled | IHME |
| 6.87 (5.31 - 8.79) | 2015 | Modelled | IHME |
| 6.66 (5.08 - 8.46) | 2014 | Modelled | IHME |
| 7.27 (5.59 - 9.31) | 2013 | Modelled | IHME |
| 7.54 (5.76 - 9.71) | 2012 | Modelled | IHME |
| 7.49 (5.71 - 9.62) | 2011 | Modelled | IHME |
| 7.82 (5.97 - 9.99) | 2010 | Modelled | IHME |
| 8.43 (6.42 - 10.80) | 2009 | Modelled | IHME |
| 9.8 (7.55 - 12.40) | 2008 | Modelled | IHME |
| 11.3 (8.77 - 14.20) | 2007 | Modelled | IHME |
| 12.3 (9.63 - 15.40) | 2006 | Modelled | IHME |
| 12.4 (9.73 - 15.48) | 2005 | Modelled | IHME |
| 13.3 (10.40 - 16.50) | 2004 | Modelled | IHME |
| 13.9 (10.90 - 17.40) | 2003 | Modelled | IHME |
| 13.5 (10.60 - 17) | 2002 | Modelled | IHME |
| 13.9 (10.80 - 17.30) | 2001 | Modelled | IHME |
| 13.36 (10.50 - 16.60) | 2000 | Modelled | IHME |
| 13.3 (10.40 - 16.50) | 1999 | Modelled | IHME |
| 13 (10.10 - 16.10) | 1998 | Modelled | IHME |
| 12.7 (9.91 - 15.60) | 1997 | Modelled | IHME |
| 12.5 (9.35 - 16.20) | 1996 | Modelled | IHME |
| 12.4 (8.96 - 16.70) | 1995 | Modelled | IHME |
| 12.4 (8.79 - 16.90) | 1994 | Modelled | IHME |
| 12.4 (8.61 - 17.40) | 1993 | Modelled | IHME |
| 12.4 (8.65 - 17.20) | 1992 | Modelled | IHME |
| 12.5 (8.68 - 17.30) | 1991 | Modelled | IHME |
| 12.6 (8.65 - 17.40) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 147 (103 - 209) | 2019 | Modelled | IHME |
| 145 (103 - 204) | 2018 | Modelled | IHME |
| 144 (107 - 189) | 2017 | Modelled | IHME |
| 141 (107 - 183) | 2016 | Modelled | IHME |
| 142 (110 - 182) | 2015 | Modelled | IHME |
| 137 (105 - 175) | 2014 | Modelled | IHME |
| 150 (115 - 192) | 2013 | Modelled | IHME |
| 155 (118 - 199) | 2012 | Modelled | IHME |
| 153 (117 - 197) | 2011 | Modelled | IHME |
| 160 (122 - 204) | 2010 | Modelled | IHME |
| 171 (131 - 219) | 2009 | Modelled | IHME |
| 199 (153 - 251) | 2008 | Modelled | IHME |
| 228 (177 - 286) | 2007 | Modelled | IHME |
| 248 (194 - 310) | 2006 | Modelled | IHME |
| 250 (195 - 311) | 2005 | Modelled | IHME |
| 266 (209 - 329) | 2004 | Modelled | IHME |
| 278 (218 - 347) | 2003 | Modelled | IHME |
| 270 (212 - 339) | 2002 | Modelled | IHME |
| 278 (216 - 345) | 2001 | Modelled | IHME |
| 266 (209 - 331) | 2000 | Modelled | IHME |
| 264 (207 - 328) | 1999 | Modelled | IHME |
| 259 (201 - 321) | 1998 | Modelled | IHME |
| 253 (197 - 311) | 1997 | Modelled | IHME |
| 248 (186 - 323) | 1996 | Modelled | IHME |
| 247 (178 - 331) | 1995 | Modelled | IHME |
| 247 (175 - 336) | 1994 | Modelled | IHME |
| 247 (171 - 345) | 1993 | Modelled | IHME |
| 244 (171 - 340) | 1992 | Modelled | IHME |
| 248 (172 - 343) | 1991 | Modelled | IHME |
| 249 (170 - 344) | 1990 | Modelled | IHME |
| 165 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 20 (14 - 28) | 2019 | Modelled | IHME |
| 21 (14 - 29) | 2018 | Modelled | IHME |
| 21 (15 - 29) | 2017 | Modelled | IHME |
| 21 (15 - 29) | 2016 | Modelled | IHME |
| 21 (14 - 29) | 2015 | Modelled | IHME |
| 21 (14 - 29) | 2014 | Modelled | IHME |
| 21 (15 - 29) | 2013 | Modelled | IHME |
| 21 (15 - 29) | 2012 | Modelled | IHME |
| 21 (15 - 30) | 2011 | Modelled | IHME |
| 21 (15 - 30) | 2010 | Modelled | IHME |
| 22 (15 - 30) | 2009 | Modelled | IHME |
| 23 (16 - 31) | 2008 | Modelled | IHME |
| 23 (17 - 32) | 2007 | Modelled | IHME |
| 24 (17 - 33) | 2006 | Modelled | IHME |
| 25 (17 - 34) | 2005 | Modelled | IHME |
| 25 (18 - 34) | 2004 | Modelled | IHME |
| 25 (18 - 34) | 2003 | Modelled | IHME |
| 25 (17 - 34) | 2002 | Modelled | IHME |
| 25 (17 - 34) | 2001 | Modelled | IHME |
| 25 (18 - 34) | 2000 | Modelled | IHME |
| 25 (18 - 34) | 1999 | Modelled | IHME |
| 25 (18 - 34) | 1998 | Modelled | IHME |
| 24 (18 - 33) | 1997 | Modelled | IHME |
| 24 (17 - 33) | 1996 | Modelled | IHME |
| 24 (17 - 33) | 1995 | Modelled | IHME |
| 24 (17 - 33) | 1994 | Modelled | IHME |
| 24 (17 - 33) | 1993 | Modelled | IHME |
| 24 (17 - 33) | 1992 | Modelled | IHME |
| 24 (17 - 33) | 1991 | Modelled | IHME |
| 24 (17 - 32) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 85 (65 - 122) | 2014 | Survey/reported | Slovenia National Institute of Public Health, 2014. |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 62 | 2016 | Survey/reported | EMCDDA, 2019 |
| 62 | 2017 | Survey/reported | ECDC |
| 62 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.22 (0.99 - 1.51) | 2019 | Modelled | IHME |
| 1.21 (0.98 - 1.48) | 2018 | Modelled | IHME |
| 1.2 (0.98 - 1.46) | 2017 | Modelled | IHME |
| 1.2 (0.98 - 1.46) | 2016 | Modelled | IHME |
| 1.2 (0.97 - 1.47) | 2015 | Modelled | IHME |
| 1.21 (0.98 - 1.47) | 2014 | Modelled | IHME |
| 1.21 (0.99 - 1.47) | 2013 | Modelled | IHME |
| 1.22 (0.99 - 1.48) | 2012 | Modelled | IHME |
| 1.22 (1 - 1.48) | 2011 | Modelled | IHME |
| 1.23 (1 - 1.49) | 2010 | Modelled | IHME |
| 1.23 (1 - 1.49) | 2009 | Modelled | IHME |
| 1.23 (1.01 - 1.51) | 2008 | Modelled | IHME |
| 1.24 (1.01 - 1.53) | 2007 | Modelled | IHME |
| 1.24 (1.01 - 1.54) | 2006 | Modelled | IHME |
| 1.25 (1.01 - 1.55) | 2005 | Modelled | IHME |
| 1.25 (1.02 - 1.55) | 2004 | Modelled | IHME |
| 1.26 (1.03 - 1.55) | 2003 | Modelled | IHME |
| 1.26 (1.03 - 1.55) | 2002 | Modelled | IHME |
| 1.27 (1.04 - 1.55) | 2001 | Modelled | IHME |
| 1.27 (1.03 - 1.55) | 2000 | Modelled | IHME |
| 1.27 (1.03 - 1.55) | 1999 | Modelled | IHME |
| 1.27 (1.03 - 1.54) | 1998 | Modelled | IHME |
| 1.27 (1.03 - 1.55) | 1997 | Modelled | IHME |
| 1.27 (1.03 - 1.55) | 1996 | Modelled | IHME |
| 1.27 (1.03 - 1.55) | 1995 | Modelled | IHME |
| 1.27 (1.03 - 1.55) | 1994 | Modelled | IHME |
| 1.27 (1.03 - 1.56) | 1993 | Modelled | IHME |
| 1.26 (1.02 - 1.56) | 1992 | Modelled | IHME |
| 1.26 (1.02 - 1.55) | 1991 | Modelled | IHME |
| 1.25 (1.01 - 1.54) | 1990 | Modelled | IHME |
| 0.3 (0.20 - 0.30) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.35 (0.24 - 0.40) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 30.5 (26.40 - 34.50) | 2014 | Modelled | Degenhardt L et al, 2017 |
| 32.1 (23.60 - 41.60) | 2009 | Survey/reported | EMCDDA |
| 42.62 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Pregnant women
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.1 (0.10 - 0.20) | 2013 | Survey/reported | Kopilovic B PM et al, 2015 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 24,701 (20,000 - 30,369) | 1990 | Modelled | IHME |
| 24,855 (20,057 - 30,556) | 1991 | Modelled | IHME |
| 24,989 (20,244 - 30,794) | 1992 | Modelled | IHME |
| 25,100 (20,410 - 30,840) | 1993 | Modelled | IHME |
| 25,184 (20,434 - 30,730) | 1994 | Modelled | IHME |
| 25,237 (20,402 - 30,852) | 1995 | Modelled | IHME |
| 25,269 (20,442 - 30,775) | 1996 | Modelled | IHME |
| 25,292 (20,528 - 30,782) | 1997 | Modelled | IHME |
| 25,306 (20,578 - 30,732) | 1998 | Modelled | IHME |
| 25,317 (20,592 - 30,771) | 1999 | Modelled | IHME |
| 25,328 (20,613 - 30,807) | 2000 | Modelled | IHME |
| 25,307 (20,644 - 30,976) | 2001 | Modelled | IHME |
| 25,239 (20,644 - 30,965) | 2002 | Modelled | IHME |
| 25,151 (20,548 - 31,064) | 2003 | Modelled | IHME |
| 25,068 (20,416 - 30,983) | 2004 | Modelled | IHME |
| 25,020 (20,316 - 31,049) | 2005 | Modelled | IHME |
| 25,005 (20,401 - 30,896) | 2006 | Modelled | IHME |
| 25,001 (20,369 - 30,810) | 2007 | Modelled | IHME |
| 25,007 (20,369 - 30,562) | 2008 | Modelled | IHME |
| 25,021 (20,340 - 30,375) | 2009 | Modelled | IHME |
| 25,033 (20,360 - 30,311) | 2010 | Modelled | IHME |
| 25,024 (20,439 - 30,246) | 2011 | Modelled | IHME |
| 24,989 (20,391 - 30,352) | 2012 | Modelled | IHME |
| 24,942 (20,350 - 30,318) | 2013 | Modelled | IHME |
| 24,908 (20,228 - 30,264) | 2014 | Modelled | IHME |
| 24,897 (20,126 - 30,405) | 2015 | Modelled | IHME |
| 24,893 (20,323 - 30,211) | 2016 | Modelled | IHME |
| 24,903 (20,314 - 30,284) | 2017 | Modelled | IHME |
| 25,036 (20,367 - 30,606) | 2018 | Modelled | IHME |
| 25,305 (20,634 - 31,275) | 2019 | Modelled | IHME |
| 6,000 (4,000 - 7,000) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,500 (1,100 - 1,700) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 8.17 (5.74 - 11.30) | 2019 | Modelled | IHME |
| 8.1 (5.87 - 11) | 2018 | Modelled | IHME |
| 8 (6.01 - 10.50) | 2017 | Modelled | IHME |
| 7.87 (6.14 - 9.98) | 2016 | Modelled | IHME |
| 7.92 (6.21 - 10) | 2015 | Modelled | IHME |
| 7.68 (5.97 - 9.80) | 2014 | Modelled | IHME |
| 8.25 (6.46 - 10.60) | 2013 | Modelled | IHME |
| 8.47 (6.65 - 10.80) | 2012 | Modelled | IHME |
| 8.35 (6.48 - 10.60) | 2011 | Modelled | IHME |
| 8.58 (6.64 - 11) | 2010 | Modelled | IHME |
| 8.51 (6.56 - 11) | 2009 | Modelled | IHME |
| 8.43 (6.51 - 11) | 2008 | Modelled | IHME |
| 8.28 (6.38 - 10.80) | 2007 | Modelled | IHME |
| 7.94 (6.13 - 10.30) | 2006 | Modelled | IHME |
| 7.64 (5.92 - 10) | 2005 | Modelled | IHME |
| 8.09 (6.12 - 10.70) | 2004 | Modelled | IHME |
| 8.38 (6.36 - 11.10) | 2003 | Modelled | IHME |
| 8.23 (6.19 - 10.90) | 2002 | Modelled | IHME |
| 8.47 (6.49 - 11.30) | 2001 | Modelled | IHME |
| 8.14 (6.14 - 10.80) | 2000 | Modelled | IHME |
| 8.08 (6.11 - 10.70) | 1999 | Modelled | IHME |
| 7.9 (5.96 - 10.50) | 1998 | Modelled | IHME |
| 7.71 (5.83 - 10.30) | 1997 | Modelled | IHME |
| 7.52 (5.43 - 10.30) | 1996 | Modelled | IHME |
| 7.45 (5.17 - 10.60) | 1995 | Modelled | IHME |
| 7.46 (5.01 - 10.60) | 1994 | Modelled | IHME |
| 7.45 (5.09 - 10.70) | 1993 | Modelled | IHME |
| 7.41 (4.95 - 10.90) | 1992 | Modelled | IHME |
| 7.54 (4.99 - 10.90) | 1991 | Modelled | IHME |
| 7.63 (5.08 - 11) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 169 (119 - 235) | 2019 | Modelled | IHME |
| 168 (122 - 229) | 2018 | Modelled | IHME |
| 166 (125 - 218) | 2017 | Modelled | IHME |
| 163 (127 - 207) | 2016 | Modelled | IHME |
| 164 (128 - 207) | 2015 | Modelled | IHME |
| 158 (123 - 202) | 2014 | Modelled | IHME |
| 170 (133 - 217) | 2013 | Modelled | IHME |
| 174 (137 - 221) | 2012 | Modelled | IHME |
| 171 (133 - 217) | 2011 | Modelled | IHME |
| 175 (135 - 225) | 2010 | Modelled | IHME |
| 173 (133 - 223) | 2009 | Modelled | IHME |
| 171 (132 - 222) | 2008 | Modelled | IHME |
| 167 (129 - 217) | 2007 | Modelled | IHME |
| 160 (123 - 207) | 2006 | Modelled | IHME |
| 153 (119 - 201) | 2005 | Modelled | IHME |
| 162 (123 - 213) | 2004 | Modelled | IHME |
| 168 (127 - 222) | 2003 | Modelled | IHME |
| 164 (124 - 217) | 2002 | Modelled | IHME |
| 169 (129 - 225) | 2001 | Modelled | IHME |
| 162 (122 - 214) | 2000 | Modelled | IHME |
| 161 (122 - 213) | 1999 | Modelled | IHME |
| 157 (119 - 209) | 1998 | Modelled | IHME |
| 153 (116 - 205) | 1997 | Modelled | IHME |
| 150 (108 - 205) | 1996 | Modelled | IHME |
| 148 (103 - 211) | 1995 | Modelled | IHME |
| 148 (99 - 210) | 1994 | Modelled | IHME |
| 148 (101 - 213) | 1993 | Modelled | IHME |
| 147 (98 - 215) | 1992 | Modelled | IHME |
| 149 (99 - 215) | 1991 | Modelled | IHME |
| 150 (100 - 217) | 1990 | Modelled | IHME |
| 184 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 28 (20 - 36) | 2019 | Modelled | IHME |
| 28 (20 - 36) | 2018 | Modelled | IHME |
| 28 (20 - 37) | 2017 | Modelled | IHME |
| 28 (20 - 36) | 2016 | Modelled | IHME |
| 28 (20 - 36) | 2015 | Modelled | IHME |
| 28 (20 - 36) | 2014 | Modelled | IHME |
| 27 (20 - 36) | 2013 | Modelled | IHME |
| 27 (19 - 36) | 2012 | Modelled | IHME |
| 27 (19 - 36) | 2011 | Modelled | IHME |
| 27 (19 - 36) | 2010 | Modelled | IHME |
| 27 (19 - 36) | 2009 | Modelled | IHME |
| 27 (19 - 35) | 2008 | Modelled | IHME |
| 26 (19 - 35) | 2007 | Modelled | IHME |
| 26 (18 - 34) | 2006 | Modelled | IHME |
| 26 (18 - 34) | 2005 | Modelled | IHME |
| 26 (18 - 34) | 2004 | Modelled | IHME |
| 25 (18 - 34) | 2003 | Modelled | IHME |
| 26 (18 - 34) | 2002 | Modelled | IHME |
| 26 (18 - 34) | 2001 | Modelled | IHME |
| 26 (18 - 34) | 2000 | Modelled | IHME |
| 26 (18 - 34) | 1999 | Modelled | IHME |
| 26 (18 - 34) | 1998 | Modelled | IHME |
| 26 (18 - 34) | 1997 | Modelled | IHME |
| 26 (18 - 34) | 1996 | Modelled | IHME |
| 26 (18 - 34) | 1995 | Modelled | IHME |
| 26 (18 - 34) | 1994 | Modelled | IHME |
| 26 (18 - 34) | 1993 | Modelled | IHME |
| 26 (18 - 34) | 1992 | Modelled | IHME |
| 26 (18 - 34) | 1991 | Modelled | IHME |
| 26 (19 - 35) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 85 (65 - 122) | 2014 | Survey/reported | Slovenia National Institute of Public Health, 2014. |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 62 | 2016 | Survey/reported | EMCDDA, 2019 |
| 62 | 2017 | Survey/reported | ECDC |
| 62 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Number of persons treated for HCV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 172 | 2017 | Survey/reported | ECDC, 2019 |
| 172 | 2017 | Survey/reported | The European Centre for Disease Prevention and Control, 2019 |
Showing out of
Show more
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Prevalence < 5
HBV
0.06
(%)
2019, latest modelled
(0.04 - 0.08(%))
IHME
Prevalence PWID
HCV
42.62
(%)
2017, survey/surveillance
ECDC
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
HCV
85
2014
(65 - 122)
Slovenia National Institute of Public Health, 2014.
Eligible for HBV generic medicines
Eligible for HCV generic medicines
